Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news